Q32 Bio Inc. (QTTB)
- Previous Close
28.24 - Open
28.89 - Bid 26.97 x 100
- Ask 28.28 x 100
- Day's Range
27.51 - 28.89 - 52 Week Range
8.24 - 30.92 - Volume
28,370 - Avg. Volume
32,289 - Market Cap (intraday)
334.265M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.50
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
www.q32bio.comRecent News: QTTB
Performance Overview: QTTB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QTTB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QTTB
Valuation Measures
Market Cap
334.27M
Enterprise Value
347.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.35
Price/Book (mrq)
--
Enterprise Value/Revenue
29.49
Enterprise Value/EBITDA
-11.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.42%
Return on Equity (ttm)
--
Revenue (ttm)
-6.65M
Net Income Avi to Common (ttm)
-53.74M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
25.62M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-40.9M